Balloon predilation or direct valve implantation in TAVI for women: Insights from the DIRECTAVI study
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31086 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Pierre Robert und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of cardiology, Nimes University Hospital, Nimes, France. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Balloon Valvuloplasty, Transcatheter Aortic Valve Replacement, Aortic Valve. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The randomized DIRECTAVI trial demonstrated safety and feasibility of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) using SAPIEN 3 balloon‐expandable devices. However, the female population with smaller anatomy may have potential higher risk of residual gradient and/or mismatch.
Purpose
We assessed the impact of BAV on the procedural success rate and clinical outcomes in the female population of the DIRECTAVI trial.
Methods
Between May 2016 and May 2018, 91 of the 250 patients included in the DIRECTAVI trial were women (38.6%), 45 of them (49.5%) were enrolled in the BAV group and 46 of them (50.5%) in the direct TAVI group. The primary endpoint was procedural success rate in women (Valve Academic Research Consortium‐2 criteria). The secondary endpoint included evaluation of PPM and 1‐month major adverse events according to the implantation stategy in women and comparison between men and women regarding major endpoints.
Results
The primary endpoint occurred in 29 women (64.4%) in the BAV group and in 34 women (73.9%) in the direct TAVI group (mean difference 9.47%; 95% confidence interval: 6.5%–25.4%; p = 0.045 for non‐inferiority of the direct strategy). One‐month major adverse events were similar between the 2 women groups. Procedural success was lower in women vs men ( p = 0.01) due to higher incidence of moderate mismatches in women ( p = 0.001) but with no significant difference regarding the implantation strategy ( p = 0.4).
Conclusion
Direct implantation of the balloon‐expandable SAPIEN 3 valve was non‐inferior to predilatation on procedural success in women. Incidence of moderate mismatch was higher in women but was not related to the implantation strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of cardiology, Nimes University Hospital, Nimes, France.
- Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France.
- Department of Cardiovascular Surgery, Montpellier University Hospital, Montpellier, France.
- Department of Cardiology, Montpellier University Hospital, Montpellier, France.
ORCID-Profile: Mariama Akodad, Benoit Lattuca, Thomas Gandet, Francois Roubille
Zitieren
APA
Robert, P., Akodad, M., Lattuca, B., Gandet, T., Meunier, P. A., Macia, J. C., Schmutz, L., Steinecker, M., Roubille, F., Cayla, G., & Leclercq, F. (2024). Balloon predilation or direct valve implantation in TAVI for women: Insights from the DIRECTAVI study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31086
Vancouver
Robert P, Akodad M, Lattuca B, Gandet T, Meunier PA, Macia JC, et al. Balloon predilation or direct valve implantation in TAVI for women: Insights from the DIRECTAVI study. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31086
BibTeX
@article{Robert2024,
author = {Robert, Pierre and Akodad, Mariama and Lattuca, Benoit and Gandet, Thomas and Meunier, Pierre Alain and Macia, Jean-Christophe and Schmutz, Laurent and Steinecker, Matthieu and Roubille, Francois and Cayla, Guillaume and Leclercq, Florence},
title = {Balloon predilation or direct valve implantation in TAVI for women: Insights from the DIRECTAVI study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31086}
}
EUVIMED